Anti-TIE2 antibodies and uses thereof
The present invention provides antibodies that bind to Tie2 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Tie2 and block the interaction between Tie2 and one or more Tie2 ligands such as angiopoietin 1 (Ang1), angiopoietin 2 (Ang2), angiopoietin 3 (Ang3) and/or angiopoietin 4 (Ang4). The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Tie2 biological activities including angiogenesis.
1. A pharmaceutical composition comprising an isolated antibody or antigen-binding fragment thereof that specifically binds human Tie2, wherein the antibody or antigen-binding fragment comprises the complementarity determining regions (CDRs) of an antibody produced from a cell line deposited with the ATCC under accession number PTA-12295, and a pharmaceutically acceptable carrier or diluent.
2. The pharmaceutical composition of claim 1 , wherein the antibody or antigen-binding fragment interacts with amino acids 96-106 of SEQ ID NO:7, amino acids 139-152 of SEQ ID NO:7, and amino acids 166-175 of SEQ ID NO:7, as determined by hydrogen/deuterium exchange, and blocks the interaction between Tie2 and a Tie2 ligand.
3. The pharmaceutical composition of claim 2 , wherein the Tie2 ligand is selected from the group consisting of angiopoietin 1 (Ang1), Ang2, Ang3 and Ang4.
4. The pharmaceutical composition of claim 3 , wherein the antibody or antigen-binding fragment blocks the interaction between Tie2 and all four of Ang1, Ang2, Ang3 and Ang4.
5. The pharmaceutical composition of claim 1 , wherein the antibody or antigen-binding fragment comprises the heavy chain variable region (HCVR) and light chain variable region (LCVR) of the antibody produced from the cell line deposited with the ATCC under accession number PTA-12295.
6. The pharmaceutical composition of claim 5 , wherein the antibody or antigen-binding fragment is a human antibody.
7. The pharmaceutical composition of claim 6 , wherein the human antibody comprises a human IgG4 constant region.
8. A pharmaceutical composition comprising an isolated antibody or antigen-binding fragment thereof that specifically binds human Tie2, wherein the antibody or antigen-binding fragment comprises the complementarity determining regions (CDRs) of an antibody produced from a cell line deposited with the ATCC under accession number PTA-12296, and a pharmaceutically acceptable carrier or diluent.
9. The pharmaceutical composition of claim 8 , wherein the antibody or antigen-binding fragment comprises the heavy chain variable region (HCVR) and light chain variable region (LCVR) of the antibody produced from the cell line deposited with the ATCC under accession number PTA-12296.
10. The pharmaceutical composition of claim 9 , wherein the antibody or antigen-binding fragment is a human antibody.
11. The pharmaceutical composition of claim 10 , wherein the human antibody comprises a human IgG4 constant region.
12. A pharmaceutical composition comprising an isolated antibody or antigen-binding fragment thereof that specifically binds human Tie2 and blocks the interaction between Tie2 and a Tie2 ligand, wherein the antibody or antigen-binding fragment interacts with amino acids 96-106 of SEQ ID NO:7, amino acids 139-152 of SEQ ID NO:7, and amino acids 166-175 of SEQ ID NO:7, as determined by hydrogen/deuterium exchange, and a pharmaceutically acceptable carrier or diluent.
13. The pharmaceutical composition of claim 12 , wherein the antibody or antigen-binding fragment specifically binds a rodent Tie2 and human Tie2.
14. The pharmaceutical composition of claim 13 , wherein the rodent Tie2 is mouse Tie2 or rat Tie2.
15. The pharmaceutical composition of claim 14 , wherein the antibody or antigen-binding fragment specifically binds human, mouse and rat Tie2.
16. The pharmaceutical composition of claim 12 , wherein the Tie2 ligand is selected from the group consisting of angiopoietin 1 (Ang1), Ang2, Ang3 and Ang4.
17. The pharmaceutical composition of claim 16 , wherein the antibody or antigen-binding fragment blocks the interaction between Tie2 and all four of Ang1, Ang2, Ang3 and Ang4.